The meta-analysis demonstrated that a high HALP score was significantly associated with a decreased risk of death in patients with lung cancer, specifically showing a 49% reduced risk of mortality in the univariate analysis (HR: 0.51, 95% CI = 0.41–0.62, p < 0.001) (Supplementary Figure S1) and a 44% reduced risk in the multivariate analysis (HR: 0.56, 95% CI = 0.46–0.69, p < 0.001) (Figure 2); substantial between-study heterogeneity was observed in these analyses (I2 = 77.6% for univariate, I2 = 80.4% for multivariate). This evidence concerns the gene NAT10 and lung cancer.